Atlas Trials

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Clinical trial NCT02857920 · COMPLETED

Trial details

NCT number
NCT02857920
Sponsor
Fuda Cancer Hospital, Guangzhou
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Malignant Solid Tumour
Start date
2016-08-01
Primary completion
2017-08-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.